Allogene Therapeutics Inc (ALLO)
2.91
+0.19
(+6.99%)
USD |
NASDAQ |
Sep 27, 16:00
2.89
-0.02
(-0.69%)
After-Hours: 20:00
Allogene Therapeutics Research and Development Expense (TTM): 203.25M for June 30, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2024 | 203.25M |
| March 31, 2024 | 214.94M |
| December 31, 2023 | 242.91M |
| September 30, 2023 | 263.67M |
| June 30, 2023 | 281.34M |
| March 31, 2023 | 276.47M |
| December 31, 2022 | 256.39M |
| September 30, 2022 | 234.95M |
| June 30, 2022 | 230.03M |
| March 31, 2022 | 225.15M |
| December 31, 2021 | 220.18M |
| September 30, 2021 | 218.42M |
| Date | Value |
|---|---|
| June 30, 2021 | 211.12M |
| March 31, 2021 | 206.13M |
| December 31, 2020 | 192.99M |
| September 30, 2020 | 190.12M |
| June 30, 2020 | 178.70M |
| March 31, 2020 | 163.17M |
| December 31, 2019 | 144.54M |
| September 30, 2019 | 113.68M |
| June 30, 2019 | 84.55M |
| March 31, 2019 | 175.26M |
| December 31, 2018 | 151.86M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
113.68M
Minimum
Sep 2019
281.34M
Maximum
Jun 2023
213.41M
Average
216.68M
Median
Research and Development Expense (TTM) Benchmarks
| ICU Medical Inc | 88.51M |
| OPKO Health Inc | 84.85M |
| Envista Holdings Corp | 89.40M |
| Outset Medical Inc | 50.98M |
| AIM ImmunoTech Inc | 9.03M |